Pulmatrix, Inc. PULM
Nov 3, 2026, 3:49 PM EST
- YTD
- -37.22%
- 1 year
- -71.31%
- Market cap
- 5.11M
- Revenue (ttm)
- 11.39M
- Profit margin
- -95.18%
- EPS (ttm)
- -1.08
- Shares out
- 3.65M
- Forward P/E
- -1.28
- YTD return
- -37.22%
- 1-year return
- -71.31%
- Volume
- 55.00K
- Avg volume
- 26.47K
- Open
- 1.32
- Previous close
- 1.40
- Day's range
- 1.30 – 1.47
- 52-week range
- 1.16 – 4.99
- Beta
- 0.99
2Y -0.68 (-32.69%)
Key statistics
- Enterprise value
- -4.76M
- PEG ratio
- 0.00
- Price / sales
- 1.85
- Price / book
- 1.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -15.80%
- Free cash flow
- -8.78M
- Total cash
- 12.38M
- Total debt
- 24.00K
- Return on equity
- -58.99%
- Short % of float
- 0.19%
- 50-day average
- 4.18
- 200-day average
- 2.54
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | 0.00 | -0.71 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.87 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | 0.23 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -0.57 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -1.05 | -1.03 | +0.02 | +1.90% |
| Aug 10, 2023 | Jun 1, 2023 | -1.23 | -1.04 | +0.19 | +15.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 7, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Mar 30, 2022 | HC Wainwright & Co. | main | — | Buy |
About Pulmatrix, Inc.
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pulmatrix.com
News
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study 
Eos SENOLYTIX Presents New Preclinical Survival, Healthspan, Mechanism-Of-Action Data For Its PTC-2105 Candidate At 17th World Congress On Targeting Mitochondria 2026 
Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse 
Pulmatrix (NASDAQ:PULM) Share Price Breaks Below Fifty Day Moving Average – Here’s What Happened 
Pulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2% 
Eos SENOLYTIX Advances Lead Candidate MitoXcel Geropeptide PTC-2105 Toward First-In-Human Studies For Sarcopenia And Sarcopenic Obesity 
Eos SENOLYTIX CEO To Deliver Industry Keynote On Advancing Mitochondrial-Targeted Geropeptide Medicine; Co. Expects To Close Pulmatrix Merger In Q4 
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria - Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Your note
Sign in to keep a note on PULM — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 3.21% | 117,220 | 675.19K | Sep 29, 2024 |
| Blackrock Inc. | 1.50% | 54,899 | 316.22K | Sep 29, 2024 |
| Vanguard Group Inc | 0.96% | 35,082 | 202.07K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.81% | 29,581 | 170.39K | Sep 29, 2024 |
| State Street Corporation | 0.38% | 13,945 | 80.32K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.28% | 10,342 | 59.57K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.96% | 35,082 | 202.07K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.50% | 18,246 | 105.10K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.27% | 9,700 | 55.87K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 4,453 | 25.65K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 4,155 | 23.93K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 1,975 | 11.38K | Oct 30, 2024 |